Key facts
- HyprView’s last known valuation is $4.0M (Dec 2025).
- It has raised $730K; the latest was Seed Round ($640K) in Dec 2025.
- Notable investors include Apok Invest, Normandie Incubation.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for HyprView
- ·The full record, as it builds
Funding rounds
No funding rounds for HyprView are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HyprView
Developer of a microscopy platform designed for biomedical and pharmaceutical research. The company enhances predictive classification models in digital pathology by merging various microscopy imaging modalities to improve the quality of datasets used, enabling medical researchers to elevate the accuracy of developed computational models.
- Sector
- Information Technology
- HQ
- Caen, France
- Founded
- 2021
- Website
- hyprview.com/
- Ownership
- Privately Held (backing)
HyprView doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HyprView shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HyprView in its N-PORT filings yet. We sweep new filings monthly.